Boceprevir is an orally administered hepatitis C virus (HCV) NS3/4A serine protease inhibitor used for the treatment of chronic hepatitis C (genotype 1) infection. It is indicated for use in combination with peginterferon alfa and ribavirin in adult patients (≥18 years) with compensated liver disease, including cirrhosis, who are either treatment-naïve or have failed prior therapy with interferon and ribavirin. Boceprevir exerts its antiviral effect by directly binding to the NS3/4A protease active site, thereby inhibiting viral replication. It is also noted as a research compound related to novel coronavirus studies.